SNHG3 and neoplasm: As expected, western blot verified that inactivation of SNHG3 distinctly led to the elevation of phosphorylated AKT, mTOR and ERK, indicating that SNHG3-silencing triggered tumor progression in PTC by modulating AKT/mTOR/ERK signaling pathway.